Physician profile
Murray L Scheinman
NPI 1467461921
$5,121.23
in general payments reported to CMS, 2019-2025
21 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $827 · 2021: $1,068 · 2022: $788 · 2023: $640 · 2024: $321 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $796.69 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $698.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $514.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.26 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $282.36 | 2019-2024 | Eliquis |
| Allergan, INC. | $232.07 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $202.94 | 2019-2021 | |
| Exact Sciences Corporation | $199.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $179.52 | 2019-2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.10 | 2019 | |
| Abbvie INC. | $99.73 | 2020-2021 | |
| Astellas Pharma US INC | $66.66 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $63.93 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.64 | 2025 | Caplyta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $55.16 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $53.68 | 2020-2021 | |
| Amgen INC. | $46.07 | 2019-2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $29.52 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.10 | 2019 | |
| Impel Pharmaceuticals INC. | $20.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Scheinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.